Making $$ in the Market
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Appa @ Stockcharts
Nice chart!
http://finance.yahoo.com/news/p-pharma-announces-second-quarter-120000494.html
Stockcharts @ MSTX
In a report published Thursday, Canaccord Genuity analyst Ritu Baral initiated coverage on Mast Therapeutics (NYSE: MSTX [FREE Stock Trend Analysis]) with a Buy rating and $3.00 price target.
In the report, Canaccord Genuity noted, “Initiating coverage with BUY rating, $3.00 target on MST-188 potential in sickle cell disease crises. MSTX's lead candidate MST-188 binds to hydrophobic surfaces on damaged cells to reduce cell adhesion and blood viscosity. We expect positive data from the Ph3 EPIC trial that shows reduced length of SCD vaso-occlusive crisis (VOC). We think MST-188 could gain significant market share given the unmet need in SCD and potential combo-Tx. Our $3.00 target is based on pNPV analysis
http://www.benzinga.com/analyst-ratings/analyst-color/13/10/3964108/update-canaccord-genuity-initiates-coverage-on-mast-ther#
PPS:.51
HZNP @ EarningsImpact
JMP Securities 2013 Healthcare Conference Transcript
http://www.earningsimpact.com/Transcript/82080/HZNP/Horizon-Pharma-Inc---JMP-Securities-2013-Healthcare-Conference
Investor 100
BAC & C @ Stockcharts
Nice to see some continued movement in two holdings!
BAC: $14.31
http://finance.fortune.cnn.com/2013/07/17/bank-of-america-earnings-2/?iid=HP_LN
C:$51.79
http://news.yahoo.com/citigroup-reports-26-percent-rise-adjusted-quarterly-profit-120759821.html
Investor 100
PSDV: Announces Interim Data From Investigator-Sponsored Uveitis Study
PPS:$3.80
The U.S. Food & Drug Administration accepted Alimera’s resubmission of the New Drug Application for ILUVIEN for DME with a PDUFA date of October 17, 2013. pSivida will be entitled to receive 20% of the net profits (as defined) on sales of ILUVIEN for DME by Alimera and a $25 million milestone payment from Alimera if the FDA approves.
http://finance.yahoo.com/news/psivida-corp-announces-interim-data-120000291.html
Investor 100
Future Link
Stocks: Fed puts record highs within reach
http://money.cnn.com/2013/07/11/investing/premarkets/index.html?iid=Lead
Investor 100
OT:The FDA's Cancer Czar Says He Can't Approve New Drugs Fast Enough
http://www.forbes.com/sites/matthewherper/2013/06/23/the-fdas-cancer-czar-says-he-cant-approve-new-drugs-fast-enough/?partner=yahootix
Investor 100
Happy Fathers Day to all Dad's @ Sheff Station
Investor 100
OT:How sun-damaged is your skin?
Time to get the sunscreen out!
http://www.cnn.com/2013/06/04/health/sunscreen-aging/index.html?hpt=he_t4
(CNN) -- It turns out sunscreen does more than protect you from cancer and painful sunburns -- it offers a boost to simple vanity.
A new study finds that regular sunscreen use protects against photoaging: the wrinkling, spotting and loss of elasticity caused by exposure to the sun's ultraviolet radiation.
While they may not be shocking, the findings -- from Australian researchers -- are the first to quantify sunscreen's anti-aging properties.
More than 900 participants were followed for four years. Some were told to use sunscreen daily and instructed in proper use, including re-applying sunscreen after being outside for a few hours, after going in the water or after sweating heavily.
Investor 100
APRI:Apricus Biosciences Receives European Approval for Vitaros(R) for the Treatment of Erectile Dysfunction
Company to Host Conference Call Today at 9:00 AM ET
http://finance.yahoo.com/news/apricus-biosciences-receives-european-approval-110000072.html
SAN DIEGO, June 10, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (APRI) (http://www.apricusbio.com), today announced that its marketing application for Vitaros(R), indicated for the treatment of patients with erectile dysfunction ("ED"), has been approved through the European Decentralized Procedure ("DCP").
"The approval of Vitaros(R) in Europe marks a significant milestone for Apricus Bio as we continue to execute on our core strategy of developing, seeking regulatory approval, and partnering our sexual health products," said Richard Pascoe, Chief Executive Officer of Apricus Bio. "Vitaros(R) has a unique product profile that meets the needs of a large number of patients suffering from erectile dysfunction and who are intolerant to or do not respond to current treatment options. With its rapid onset of action and unique topical delivery, we believe that Vitaros(R) will capture a significant share of the approximately $1 billion PDE-5 inhibitor market in Europe once it is launched by our commercial partners."
"Moreover, partnering interest in Vitaros(R) remains strong and we are actively seeking to secure additional partnerships in the remaining European and global markets," continued Pascoe. "With the completion of a $17.1 million financing, the divestiture of multiple non-core assets, and streamlining of our global operations in the second quarter of 2013, Apricus Bio is now well positioned to advance our lead assets for male and female sexual health, Vitaros(R) and Femprox(R), in an effort to create long-term shareholder value."
Under the DCP, Apricus Bio filed its application for marketing approval designating Netherlands as the Reference Member State ("RMS") on behalf of nine other European Concerned Member States ("CMS") participating in the procedure. The CMS include France, Germany, Italy, UK, Ireland, Spain, Sweden, Belgium and Luxembourg. The Company will continue to work independently as well as with its commercialization partners, Sandoz, Takeda, and Bracco for the next step of obtaining national phase approvals in order to make Vitaros(R) ready to launch in each of the included territories across Europe.
Conference Call Information
The call will take place today, June 10 at 9:00 AM ET and can be accessed in the U.S. by dialing 877-407-9210 and outside of the U.S. by dialing 201-689-8049 and asking the conference operator for the Apricus Bio Conference Call. The conference call will also be webcast live at www.investorcalendar.com/IC/CEPage.asp?ID=171060. The teleconference replay will be available for three months by dialing in the U.S. 877-660-6853 and outside of the U.S. by dialing 201-612-7415. Replay Passcode 415699 is required for playback. The webcast replay will be available for three months.
About Vitaros(R)
Vitaros(R) is a topically-applied cream formulation of alprostadil, a vasodilator, combined with our proprietary permeation enhancer DDAIP.HCL, which directly increases blood flow to the penis, causing an erection. Alprostadil is a widely accepted alternative to the PDE-5 inhibitors for difficult to treat patients, and Vitaros(R), which was determined to be safe and effective by the European Health Authorities and previously by Health Canada, offers greater market opportunity due to its patient-friendly form versus other alprostadil dosage forms and also relative to oral ED products. With a market affecting nearly 150 million men worldwide and representing approximately $1 billion in revenue in Europe, Vitaros(R) represents a major market opportunity, particularly as a distinct product that addresses a significant underserved population.
About Femprox(R)
Femprox(R) is our product candidate for the treatment of female sexual arousal disorder (FSAD) which contains a topically-applied cream formulation of alprostadil, a vasodilator, and our proprietary permeation enhancer DDAIP.HCL. Seven clinical studies have been successfully completed to date, including one, 98-subject Phase 2 study in the US and a nearly 400-subject Phase 3 study in China. To date, no product has been approved in the U.S. to treat FSAD, a persistent or recurring inability to attain or maintain adequate sexual excitement, causing personal distress. Estimates of the FSAD market size put it on par with erectile dysfunction in males, and possibly larger.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a pharmaceutical company that develops and markets innovative treatments that help large patient populations across numerous, large-market therapeutic classes including male and female sexual health. The Company has one approved product, Vitaros(R), for the treatment of erectile dysfunction, which is now approved in Europe and Canada and will be commercialized by Apricus Bio's marketing partners which include, Abbott Canada, Takeda Pharmaceuticals International GmbH, Sandoz, and Bracco SpA. Femprox(R), the Company's product candidate for the treatment of female sexual arousal disorder, has successfully completed a nearly 400-subject Phase 3 study in China.
For further information on Apricus Bio, visit http://www.apricusbio.com.
Apricus Bio's Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, its ability to further develop its product Vitaros(R) for erectile dysfunction , and product candidate Femprox(R) for Female Sexual Arousal Disorder among others; to have its product and product candidates receive additional patent protection and be approved by relevant regulatory authorities in Europe, the United States and Canada and in other countries; to successfully commercialize such product and product candidates and other NexACT(R) product candidates and drug delivery technology; to sell its oncology supportive care business or assets to a third party or parties; to cease funding to its French subsidiaries and to have such subsidiaries reorganize or liquidate successfully; and to achieve its other development, commercialization and financial goals. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
Investor 100
Futures Link
http://www.finviz.com/futures.ashx
Investor 100
OT:AstraZeneca Buys Pearl for Up to $1.15 Billion
http://www.cnbc.com/id/100802043
AstraZeneca is to buy U.S. respiratory drug specialist Pearl Therapeutics for up to $1.15 billion, as Britain's second biggest drugmaker steps up a drive to rebuild its product pipeline via deal-making.
The acquisition of the privately held company secures AstraZeneca a position in the emerging market for a new class of lung treatments known as LABA/LAMA drugs that promise improved patient compliance and disease control, without steroids.
Some industry analysts believe that LABA/LAMA inhalers are set to dominate future therapy for chronic obstructive pulmonary disease (COPD), which causes debilitating breathlessness and affects an estimated 210 million people worldwide.
(Read More: Valeant, AstraZeneca in Two Big Pharma M&A Deals )
AstraZeneca said on Monday it will pay an initial $560 million plus up to $450 million if certain development milestones are hit as well as sales-related payments of up to a further $140 million.
The transaction is an important bet by new chief executive Pascal Soriot, who took over last October, on the British company's respiratory business, which he has identified as a core business area.
AstraZeneca's sales and profits are falling as older medicines lose patent protection and the company badly needs new products to replace former big sellers like the antipsychotic Seroquel, which lost exclusivity last year.
It already has a successful existing inhaled respiratory drug in Symbicort but had risked falling behind rivals like GlaxoSmithKline and Novartis in the race to bring LABA/LAMA inhalers to market.
Investor 100
Furure Link
http://www.finviz.com/futures.ashx
Investor 100
DYAX:Dyax Announces $30 Million Offering
http://finance.yahoo.com/news/dyax-announces-30-million-offering-111500299.html
Investor 100
Future Link
http://www.finviz.com/futures.ashx
Investor 100
Future Link
http://www.finviz.com/futures.ashx
Investor 100
Future Link
http://www.finviz.com/futures.ashx
Investor 100
INO:Inovio receives $3.5M biodefense grant for mass vaccination device
PPS:.57
http://finance.yahoo.com/news/inovio-receives-3-5m-biodefense-130248693.html
Inovio has been selected to receive a $3.5M grant from the National Institute of Allergy and Infectious Diseases to advance the development of its next generation DNA vaccine delivery device capable of simultaneously administering multiple synthetic vaccines via skin surface electroporation. Inovio is collaborating with Dr. Connie Schmaljohn, Chief Scientist at the U.S. Army Medical Research Institute of Infectious Diseases. The goal of this public/private partnership is to develop a device that would facilitate rapid vaccination of U.S. troops stationed around the world against multiple infectious diseases and protect civilian populations from pandemic threats.
Investor 100
CYCC:AACR Press Conference Highlights Combination Potential of Two Cyclacel Drugs
Novel Drug Combination Active in Patients With Incurable BRCA-Deficient Cancers
WASHINGTON, April 8, 2013 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (CYCC) (CYCCP) ("Cyclacel" or the "Company") today announced that the American Association of Cancer Research (AACR) highlighted data at a press conference in Washington, D.C. from a clinical trial evaluating a novel combination regimen of two of the Company's orally available, experimental drugs, sapacitabine and seliciclib. The trial enrolled patients with an incurable form of cancer associated with BRCA defects in the patients' genome. The press conference was held yesterday on the occasion of the American Association of Cancer Research (AACR) Annual Meeting 2013 which opened here this weekend.
http://finance.yahoo.com/news/aacr-press-conference-highlights-combination-110000257.html
Investor 100
NBY:NovaBay Global Ophthalmology Study Enrolls First Patients in Brazil
EMERYVILLE, Calif., April 8, 2013 (GLOBE NEWSWIRE) -- NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT:NBY), a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with first-in-class compounds such as its proprietary Aganocides(R), today announced the enrollment of the first patients in Brazil into its global Phase 2b clinical trial, BAYnovation. The trial is investigating Auriclosene (NVC-422) Ophthalmic Solution as a treatment for adenoviral conjunctivitis, a highly contagious form of "pink eye" for which there is no approved treatment anywhere in the world.
http://finance.yahoo.com/news/novabay-global-ophthalmology-study-enrolls-110000997.html
Investor 100
ARIA:ARIAD Presents New Preclinical Data Showing Ponatinib is a Potent Inhibitor of RET and FGFR, Two Oncogenic Drivers of Non-Small Cell Lung Cancer
CAMBRIDGE, Mass. & WASHINGTON--(BUSINESS WIRE)--
ARIAD Pharmaceuticals, Inc. (ARIA) today announced the presentation of preclinical data on ponatinib (Iclusigâ„¢) , at the American Association for Cancer Research (AACR) Annual Meeting 2013, in Washington. In separate studies, ponatinib is shown to potently inhibit RET, a clinically proven oncogenic driver of medullary thyroid cancer (MTC) and non-small cell lung cancer (NSCLC), and FGFR, which is commonly mutated in endometrial, lung and other cancers.
http://finance.yahoo.com/news/ariad-presents-preclinical-data-showing-113500528.html
Investor 100
AMRN:Amarin Announces New Clinical Data Showing Significant Reductions in Apolipoprotein C-III Levels in MARINE and ANCHOR Studies of Vascepa(R)
http://finance.yahoo.com/news/amarin-announces-clinical-data-showing-100000785.html
Investor 100
DCTH:DELCATH RECEIVES NOTIFICATION OF PDUFA DATE EXTENSION
NEW YORK, NY - April 8, 2013 - Delcath Systems, Inc. (DCTH) today announced that the U.S. Food and Drug Administration (FDA) has extended the initial Prescription Drug User Fee Act (PDUFA) goal date for its review of the Company`s New Drug Application (NDA) for the marketing approval of MelblezTM Kit (Melblez (melphalan) for Injection for use with the Delcath Hepatic Delivery System), the Company`s proprietary drug/device combination product for the treatment of patients with unresectable ocular melanoma metastatic to the liver
http://finance.yahoo.com/news/delcath-receives-notification-pdufa-date-103202031.html
Investor 100
APPA @ Stockcharts
PPS:.0624
http://www.biopharmcatalyst.com/pdufa-calendar/
GLTA
Investor 100
Future Link
http://www.finviz.com/futures.ashx
Investor 100
Future Link
http://www.finviz.com/futures.ashx
Investor 100
Future Link
http://www.finviz.com/futures.ashx
Investor 100
CRIS:Curis to Present at the Roth Capital Partners 25th Annual Growth Stock Conference
PPS:$3.49
http://finance.yahoo.com/news/curis-present-roth-capital-partners-110000836.html
Investor 100
Future Link
http://www.finviz.com/futures.ashx
Investor 100
BAC & C @ Stockcharts
http://money.cnn.com/2013/03/11/investing/bank-stocks/index.html?iid=HP_LN
C:$46.68
BAC:$12.07
Investor 100
C:$29.00 Purchase
BAC:$7.10 Purchase
Sheff- Thanks for sharing your thoughts on your friend Charlie who would have inspired all of us but unfortunatly his life was taken too early - sorry to read this news! God bless Charlie and his family.
Investor 100
Sure do Sheff- some nice gainers at 3.7M but at a huge cost!
And in case you were wondering, he traded in these stocks: Adolor, Anesiva, Connetics, Cornerstone Therapeutics, CV Therapeutics, Encysive Pharmaceuticals, EPIX Pharmaceuticals, MannKind, Middlebrook Pharmaceuticals, Momenta Pharmaceuticals, Novadel Pharmaceuticals, Pharmacyclics, Pozen, Progenics Pharmaceuticals, Santarus, Somaxon Pharmaceuticals, Spectrum Pharmaceuticals and Vanda Pharmaceuticals (look at this chart).
Investor 100
INO:Inovio Pharmaceuticals Prices $15.1 Million Offering of Common Stock and Warrants
PPS:$.52
http://finance.yahoo.com/news/inovio-pharmaceuticals-prices-15-1-110000170.html
Investor 100
HZNP:Horizon Pharma Receives Marketing Authorization for DUEXIS(R) From the United Kingdom Medicines and Healthcare Products Regulatory Agency
PPS:$2.32
http://finance.yahoo.com/news/horizon-pharma-receives-marketing-authorization-123000970.html
Investor 100